• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Magnesium not associated with neuroprotection in preterm chorioamnionitis

byDenise PongandLeah Hawkins Bressler, MD, MPH
June 7, 2015
in Obstetrics, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Rates of severe neonatal and childhood morbidity were similar between preterm infants whose mothers received magnesium sulfate compared to placebo.

2. The proportion of infants with low mental developmental scores was lower in the magnesium group but failed to achieve significance.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Cerebral palsy (CP) is a common, heterogeneous non-progressive neuromuscular clinical syndrome. It is characterized by a combination of motor and postural dysfunction and other neurologic signs that can result in lifelong disability. Risk factors include prematurity, intrauterine growth restriction, and intrauterine infection. While there is no definitive treatment for CP, administration of antenatal magnesium sulfate during preterm labor has been shown to decrease the incidence and severity of CP. The mechanism by which magnesium sulfate acts is unknown, but evidence suggests it modifies inflammatory cytokines that may play a role in the development of CP. A landmark trial defined the benefit of magnesium sulfate administration to women in preterm labor up to 32 weeks gestation in decreasing the incidence of CP (see relevant reading). In the present work, authors assessed whether magnesium confers neuroprotection among a subset of preterm infants exposed to chorioamnionitis. They found that outcomes were similar among infants who received magnesium sulfate and placebo.

Strengths of the investigation included randomized controlled trial design, prospective data collection and evaluation of long-term outcomes. Limitations included post hoc analysis and small sample size which increases the risk of Type II error (erroneous failure to reject the null hypothesis). Additional investigation to better characterize which patients benefit most from this treatment is merited.

Click to read the study in BJOG

Relevant Reading: The BEAM trial (Beneficial Effects of Antenatal Magnesium Sulfate)

RELATED REPORTS

Antenatal corticosteroids may affect neurodevelopment differently based on gestational age

In utero exposure to maternal SARS-CoV-2 infection not associated with neurodevelopmental deficits at 6 months

Neurodevelopmental outcomes of extremely preterm newborns improved since 1990s

In-Depth [randomized controlled trial]: This secondary analysis of a randomized clinical trial evaluated the neuroprotective effects of magnesium sulfate in preterm infants of women diagnosed with chorioamnionitis. Women at risk of delivery between 24 and 0/7 and 31 and 6/7 weeks gestation with a clinical diagnosis of chorioamnionitis and temperature >37.8°C or receiving antibiotics for chorioamnionitis were randomized to receive magnesium sulfate (n = 192) or placebo (n = 204). The primary outcome was a composite of severe childhood morbidity encompassing stillbirth or death before age 1 and moderate or severe CP at or after age 2. Secondary outcomes included neonatal morbidities such as sepsis, intraventricular hemorrhage, necrotizing enterocolitis, and developmental delay.

There were no differences in severe composite childhood morbidity (p = 0.42), composite neonatal morbidity (p = 0.27) or developmental delay. Similarly, there were no differences in the composite primary outcome in a subgroup of very preterm infants <28 weeks gestational age. Infants born to women who received antenatal magnesium experienced an insignificantly lower risk of low mental developmental score (RR: 0.67, p = 0.10).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Magnesiumneurodevelopment
Previous Post

Cardiac risk factors associated with noncalcified plaque burden in asymptomatic patients

Next Post

Improved recovery from vaginal surgery with dexamethasone

RelatedReports

Abusive head trauma results in fewer productive life-years
Chronic Disease

Antenatal corticosteroids may affect neurodevelopment differently based on gestational age

April 28, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

In utero exposure to maternal SARS-CoV-2 infection not associated with neurodevelopmental deficits at 6 months

January 11, 2022
Digital imaging detects sight-threatening retinopathy of prematurity
Neurology

Neurodevelopmental outcomes of extremely preterm newborns improved since 1990s

July 20, 2021
Foster placement not sole factor in lagging academic achievement
Chronic Disease

Preterm birth linked to higher incidence of severe neurodevelopmental disabilities at age 5

May 28, 2021
Next Post
Improved recovery from vaginal surgery with dexamethasone

Improved recovery from vaginal surgery with dexamethasone

Nonlinear relationship between maternal hemoglobin and infant development

Nonlinear relationship between maternal hemoglobin and infant development

Youth weapon violence linked to psychological consequences

Youth weapon violence linked to psychological consequences

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.